InvestorsHub Logo
Followers 21
Posts 980
Boards Moderated 0
Alias Born 03/20/2019

Re: Invest83838 post# 311007

Friday, 11/20/2020 1:14:12 PM

Friday, November 20, 2020 1:14:12 PM

Post# of 426504
If approval in China is "weeks" away with expanded label for REDUCE-IT, that will be huge.
Saw a figure where 1 in 5 adults in China have CVD.
We have a partner in China in Eddingpharm and that's the right way to do business there. Just collect the high royalties....the sheer numbers of people there can make this lucrative.

Expanded label in China plus approval in Europe -- the stock price will get moving soon and we will become very attractive to a BP.

We can let the BP deal with Hikma through its relationship with the FDA. A BP will have more leverage than we will. And let's not forget GSK v. Teva, which can give a BP more certainty around the USA market.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News